Docetaxel is under clinical development by Plus Therapeutics and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Docetaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Docetaxel overview

docetaxel (ATI-1123) is under development for the treatment of solid tumors such as breast cancer, pancreatic cancer, ovarian cancer, non-small cell lung cancer, thyroid cancer, gastric cancer, uterine cancer, urachal cancer, cervical cancer, prostate cancer, soft-tissue sarcoma and melanoma. ATI-1123 is with a brand name DocePlus is administered through intravenous route and by drip. It acts by targeting beta tubulin. It is developed based on protein stabilized liposome (PSL) nanotechnology.

It was also under development for the treatment of small cell lung cancer.

Plus Therapeutics overview

Plus Therapeutics, formerly Cytori Therapeutics Inc is a developmental-stage pharmaceutical company, which focuses on the discovery, development, and manufacturing of complex and innovative treatments for patients with cancer and other life-threatening diseases. Its pipeline of candidate drug products includes Doceplus, a patented albumin-stabilized Pegylated liposomal formulation of docetaxel; Doxoplus, a complex, injectable, generic Pegylated liposomal formulation of doxorubicin; BMEDA-chelated rhenium nanoliposome (RNL); and a co-encapsulated, doxorubicin and rhenium nanoliposome (DRNL). It uses a proprietary nanotechnology platform to reformulate and improve conventional chemotherapeutics. Plus Therapeutics is headquartered in Irvine, Texas, the US.

For a complete picture of Docetaxel’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.